• Home
  • Journal
  • Public Companies
  • Syntekabio (KOSDAQ:226330.KQ) Presents Neoantigen Prediction Technology at Cancer Immunotherapy Conference CICON22
Syntekabio (KOSDAQ:226330.KQ) Presents Neoantigen Prediction Technology at Cancer Immunotherapy Conference CICON22

Syntekabio (KOSDAQ:226330.KQ) Presents Neoantigen Prediction Technology at Cancer Immunotherapy Conference CICON22

Syntekabio (KOSDAQ:226330.KQ) Presents Neoantigen Prediction Technology at Cancer Immunotherapy Conference CICON22

Syntekabio (KOSDAQ:226330.KQ) Presents Neoantigen Prediction Technology at Cancer Immunotherapy Conference CICON22
Syntekabio (KOSDAQ:226330.KQ) Presents Neoantigen Prediction Technology at Cancer Immunotherapy Conference CICON22

New York, N.Y., United States, Sept. 26, 2022 (GLOBE NEWSWIRE) — Syntekabio (KOSDAQ:226330.KQ), a global AI drug discovery and development company, will present its neoantigen prediction technology NEO-ARS™ at the CRI-ENCI-AACR International Cancer Immunotherapy Conference (CICON22): Translating Science into Survival, Sep. 28 – Oct. 1, 2022.

Hyun Joo, Ph.D., senior principal scientist at the Syntekabio USA, will present AI-driven 3D structure-based neoantigen prediction and its implication on immuno-oncology therapy during Poster Session B. The full abstract is included in the conference app and will be available online via the AACR journal, Cancer Immunology Research.

WHAT:      AI-driven 3D structure-based neoantigen prediction and its implication on immuno-oncology therapy 

DATE:      Friday, Sep. 30 

TIME:      12:15 pm – 2:15 pm 

LOCATION:             New York Hilton Midtown, Americas Hall I  

NOTES:         Syntekabio USA President Kilyoung Kim is available to speak with the media onsite. For one-on-one meeting request and information about Syntekabio’s AI drug discovery cloud platform services, contact the New York office at +1 (212) 371-2544 or admin.usa@syntekabio.com.  

###

About Syntekabio

Syntekabio is a global artificial intelligence (AI) and big data-based drug discovery and development company, headquartered in South Korea since 2009, with its US operations bringing innovative technologies and science to create transformative medicines worldwide that are compliant with international standards to cure diseases and improve people’s lives. Find out more about DeepMatcher®, NEO-ARS™, NGS-ARS™ and PGM-ARS™ at www.syntekabio.com

For original news story, please visit https://www.prdistribution.com/news/syntekabio-kosdaq-226330-kq-presents-neoantigen-prediction-technology-at-cancer-immunotherapy-conference-cicon22/9313059

Attachment

CONTACT: Full Name : Sabina Lee
Company : Syntekabio USA | WMSG
Phone Number : 2014021400
Website : http://www.syntekabio.com
Email : wgroup@wmedical.org

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.